Communicated by: Yoshimi Takai RASSF6, a member of the tumor suppressor Ras-association domain family proteins, induces apoptosis in the caspase-dependent and caspase-independent manners. RASSF6 interacts with MDM2 and stabilizes p53. BCL-XL is a prosurvival member of BCL-2 family proteins. BCL-XL directly inhibits proapoptotic BAX and BAK.
| INTRODUCTION
RASSF6 is a member of the classical Ras-association family proteins (C-RASSFs) that has a Ras-association (RA) domain in the middle region and a coiled-coil motif named Salvador/RASSF/Hippo (SARAH) domain in the C-terminal region (Iwasa, Jiang, & Hata, 2015) . Humans have six CRASSFs, all of which are known as tumor suppressors (Avruch et al., 2012; Volodko, Gordon, Salla, Ghazaleh, & Baksh, 2014) . RASSF6 is frequently suppressed by DNA hypermethylation in human cancers, and its low expression correlates with tumor progression and short disease-free survival Djos, Martinsson, Kogner, & Carén, 2012; Guo et al., 2016; Hesson et al., 2009; Liang et al., 2014; Richter, Pfeifer, & Dammann, 2009; Richter, Zimmermann, Haag, Walesch, & Dammann, 2015; Wen et al., 2011; Ye et al., 2015) . These findings support that RASSF6 is a tumor suppressor. Enforced RASSF6 expression causes cell cycle arrest and induces apoptosis (Allen et al., 2007; Ikeda et al., 2007; Iwasa et al., 2013) . TP53 silencing overcomes RASSF6-induced cell cycle arrest and partially attenuates RASSF6-induced apoptosis (Iwasa et al., 2013) . Conversely, RASSF6 depletion blocks ultraviolet-induced enhancement of p53 expression (Iwasa et al., 2013) . Stated more mechanistically, RASSF6 binds to MDM2, a major E3 ligase that regulates p53 stability, and blocks p53 degradation (Iwasa et al., 2013) . The RA domain of RASSF6 binds to the C-terminal RING-finger | Genes to Cells domain of MDM2 and plays a significant role in the regulation of p53 (Sarkar et al., 2017) . Indeed, the RA domain per se induces apoptosis and senescence via p53. Importantly, whereas the SARAH domain inhibits the interaction between the RA domain and MDM2, Ras signaling releases the RA domain from this inhibition and strengthens the interaction between RASSF6 and MDM2 (Sarkar et al., 2017) .
Human BCL2L1, a BCL2-related gene, encodes two proteins with 233 and 170 amino acid residues (Boise et al., 1993; Michels et al., 2013) . The former product is BCL-XL, which has four BCL-2 homology (BH) domains (BH1 to BH4). The latter product, BCL-XS, lacks BH1 and BH2. BCL-XL is a transmembrane protein in the mitochondria and acts as an antiapoptotic protein. BCL-XL was originally thought to bind to proapoptotic BAX or BAK and to inhibit cell death (Oltvai, Milliman, & Korsmeyer, 1993; Yang et al., 1995) . However, certain BCL-XL mutants that fail to bind BAX or BAK still block cell death, which suggests that the antiapoptotic property of BCL-XL does not solely depend on the direct inhibition of BAX or BAK (Cheng, Levine, Boise, Thompson, & Hardwick, 1996; Minn et al., 1999) . Indeed, BCL-XL interacts with and traps tBID, the proapoptotic activator BH3-only protein, that activates BAX or BAK to lead to mitochondrial outer membrane permeabilization (Cheng et al., 2001) . BCL-XL binds voltage-dependent anion channel (VDAC) to regulate the permeability transition pore complex (Shimizu, Narita, & Tsujimoto, 1999) . BCL-XL interacts with and sequesters p53 (Mihara et al., 2003) . These interactions explain how BCL-XL plays an antiapoptotic role. However, in response to an apoptotic signal, the sensitizer BH3-only proteins, BAD and BIK, bind to BCL-XL and release tBID to activate BAX and BAK (Letai et al., 2002; Yang et al., 1995) .
In this study, we report the interaction between RASSF6 and BCL-XL. This interaction prompts us to conceive two scenarios. BCL-XL may block RASSF6-mediated apoptosis to enhance cell viability. Alternatively, RASSF6 may block the interaction of BCL-XL with tBID, VDAC or p53 to trigger apoptosis. Actually, we have found that BCL-XL attenuates the interaction between RASSF6 and MDM2 and antagonizes the RASSSF6-mediated stabilization of p53. Thus, BCL-XL competes with RASSF6 to balance cell survival and death.
| RESULTS

| RASSF6 interacts with BCL-XL
RASSF6 interacts with modulator of apoptosis-1 (MOAP1), which interacts with and activates BAX (Allen et al., 2007; Baksh et al., 2005; Vos et al., 2006) . We raised a question whether RASSF6 binds other BAX-interacting proteins. We exogenously expressed Myc-tagged BCL-XL and FLAGtagged RASSF6 in HEK293FT cells and immunoprecipitated FLAG-RASSF6. Myc-BCL-XL was co-immunoprecipitated with FLAG-RASSF6 ( Figure 1a , the left). As a reverse experiment, FLAG-BCL-XL was immunoprecipitated and the co-immunoprecipitation of green fluorescent protein (GFP)-RASSF6 was observed ( Figure 1a , the right). We next immunoprecipitated endogenous RASSF6 from human colon cancer SW480 cells. The immunoblotting with anti-BCL-XL antibody detected the signal with approximately 26 kDa, which corresponds to the estimated size of BCL-XL (Figure 1b) . Although we used the antibody that recognizes both BCL-XS and BCL-XL, we could not detect BCL-XS in the input and the immunoprecipitate from SW480 cells. co-immunoprecipitated with the SARAH domain of RASSF6 (RASSF6-C), but not with the RA domain (RASSF6-RA; Figure 2b ). To determine which region of BCL-XL binds RASSF6-N and RASSF6-C, we expressed mCherry-BCL-XL, mCherry-BCL-XL-N and mCherry-BCL-XL-del N with either FLAG-RASSF6-N or GFP-RASSF6-C, and examined which BCL-XL proteins were co-immunoprecipitated with RASSF6. RASSF6-N bound BCL-XL-del N, which covers BH1, BH2 and BH3, but did not interact with BCL-XL-N, which harbors BH4 (Figure 2c, arrowheads) . Similarly, RASSF6-C interacted with BCL-XL-del N, but not with BCL-XL-N (Figure 2d , arrowheads). We furthermore confirmed that RASSF6 could interact with BCL-XL-C containing BH1 and BH2 (Figure 2e , arrowheads).
| Effect of BCL-XL on the interaction between RASSF6 and various proteins related to apoptosis
RASSF6 is a proapoptotic protein (Iwasa et al., 2015) . Exogenously expressed RASSF6 induces apoptosis in various cells (Allen et al., 2007; Ikeda et al., 2007) . However, the molecular mechanism underlying RASSF6-mediated apoptosis is not yet fully clarified. RASSF6 co-operates with the tumor suppressor Hippo pathway through the interaction with mammalian Ste20-like kinase (MST) 1 and -2, the core kinases of the Hippo pathway, but induces apoptosis independently of the Hippo pathway (Ikeda et al., 2009) . One of the proposed mechanisms is that RASSF6 interacts with MOAP1 and activates BAX (Allen et al., 2007) . RASSF6 also interacts with MDM2 and blocks the MDM2-mediated degradation of p53 to cause apoptosis and cell cycle arrest via p53 (Iwasa et al., 2013) . Considering the antiapoptotic role of BCL-XL, we examined whether and how BCL-XL affects the interaction of RASSF6 with the molecules relevant to apoptosis. First, we expressed GFP-MST1 and GFP-MST2 with FLAG-RASSF6 in HEK293FT cells and immunoprecipitated FLAG-RASSF6. Myc-BCL-XL slightly reduced the amount of GFP-MST1 and GFP-MST2 coimmunoprecipitated with FLAG-RASSF6 ( Figure 3a , white arrowheads). The co-expression of Myc-BCL-XL had no effect on the interaction between FLAG-RASSF6 and GFP-MOAP1 (Figure 3b ). In contrast, Myc-BCL-XL clearly decreased the co-immunoprecipitated MDM2 (Figure 3c , a white arrowhead).
| Effect of RASSF6 on the interaction of BCL-XL with BAX, tBID, VDAC or p53
BCL-XL suppresses apoptosis through the interaction with proapoptotic proteins including BAX, tBID, VDAC and p53 (Cheng et al., 2001; Mihara et al., 2003; Oltvai et al., 1993; Shimizu et al., 1999; Yang et al., 1995) . The sensitizer BH3-only proteins, such as BAD and BIK, bind to BCL-XL and release tBID from BCL-XL to trigger apoptosis (Letai et al., 2002; Yang et al., 1995) . By analogy, we speculated that RASSF6 may release proapoptotic proteins from the inhibition by BCL-XL. We first examined the effect on F I G U R E 3 Effect of BCL-XL on various molecular interactions of RASSF6. pCIneoGFP-MST1 (a, the left), pCIneoGFP-MST2 (a, the right), pCIneoGFP-MOAP1 (b) or pCIneoGFP-MDM2 (c) was transfected into HEK293FT cells with control pCIneoFHF (the first lane), pCIneoFHF-RASSF6 (the second lane) or pCIneoFHF-RASSF6/pCIneoMyc-BCL-XL (the third lane). The immunoprecipitation was performed with anti-DYKDDDDKtag beads. Myc-BCL-XL had no effect on the interaction between RASSF6 and MOAP1, whereas it reduced the interaction of RASSF6 with MST1, MST2 and MDM2 (arrowheads) the interaction between BCL-XL and BAX. We expressed GFP-BAX and Myc-BCL-XL and immunoprecipitated Myc-BCL-XL. GFP-BAX was co-immunoprecipitated with Myc-BCL-XL ( Figure 4a , the second lane). The co-expression of FLAG-RASSF6 slightly augmented and did not reduce the interaction between BCL-XL and BAX ( Figure 4a , the third lane). Likewise, RASSF6 did not prevent BCL-XL from interacting with tBID or p53, whereas RASSF6 slightly augmented the interaction between BCL-XL and VDAC (Figure 4b-d ). In conclusion, RASSF6 is unlikely to release proapoptotic proteins from BCL-XL.
| BCL-XL suppresses RASSF6-mediated apoptosis by reducing p53
The result shown in Figure 3c suggests that BCL-XL may interfere with RASSF6-MDM2-p53 axis. Indeed, BCL-XL abrogates RASSF6-mediated enhancement of p53 expression (Figure 5a ). We previously reported that RASSF6 enhances the ubiquitination of MDM2 (Iwasa et al., 2013) . We confirmed this observation (Figure 5b , the second and the third lanes). In contrast, BCL-XL suppressed the ubiquitination of MDM2 and the RASSF6-induced enhancement of the ubiquitination (Figure 5b , the third, fourth and fifth lanes). Accordingly, BCL-XL attenuates apoptosis in cells expressing RASSF6 (Figure 6a,b) . When HCT116 cells were transfected with pCIneoGFP-RASSF6, 24 hr after transfection, almost 35% GFP-RASSF6-positive cells showed the nuclear condensation, but the co-expression of Myc-BCL-XL partially reduced the number of the cells with the nuclear condensation (Figure 6a ). We also confirmed that the co-expression of BCL-XL suppressed the cytochrome c release in HCT116 cells expressing GFP-RASSF6 (Figure 6b ). These findings support that BCL-XL antagonizes RASSF6-mediated apoptosis and enhances cell viability.
| DISCUSSION
For multicellular organisms, the delicate balance between cell survival and death is important. To maintain tissue homeostasis, damaged cells need to be removed and replaced with new cells. However, the excessive loss of cells is also detrimental. Some parts of damaged cells need to be repaired and survive. Cells must determine properly whether to be or not to be. BCL-2 family proteins play a central role in this decision (Michels et al., 2013) . The family is composed of BCL-2 homologues and related proteins. BAX and BAK harbor BH1, BH2 and BH3 and induce apoptosis (Chittenden et al., 1995; Farrow et al., 1995; Kiefer et al., 1995; Oltvai et al., 1993) . BCL-2 and BCL-XL have BH4, in addition, and exert antiapoptotic roles (Tsujimoto et al., 1984) . The family F I G U R E 4 Effect of RASSF6 on various molecular interactions of BCL-XL. HEK293FT cells were transfected with the indicated combinations of various expression constructs. In (a), GFP-BAX co-immunoprecipitated with Myc-BCL-XL was slightly increased in the presence of FLAG-RASSF6, whereas in (b) and (c), RASSF6 did not affect the interaction of BCL-XL with tBID or p53. In (d), the interaction between exogenously expressed BCL-XL and endogenous VDAC was detected. RASSF6 slightly increased the co-immunoprecipitated VDAC also includes the proteins with only BH3. Among the BH3-only proteins, tBID, BIM and PUMA directly activate BAX and BAK to induce cell death and are designated as activators (Huang, Adams, & Cory, 1998; Nakano & Vousden, 2001; Wang, Yin, Chao, Milliman, & Korsmeyer, 1996; Yu, Zhang, Hwang, Kinzler, & Vogelstein, 2001) . In contrast, the sensitizers such as BAD and BIK bind to BCL-2 and BCL-XL, release the BH3-only activators, which are trapped by these antiapoptotic BCL-2 family proteins, and eventually cause apoptosis (Boyd et al., 1995; Yang et al., 1995) . In this way, BCL-2 family proteins orchestrate cell survival and death. BCL-XL binds and inhibits proapoptotic BAX and BAK (Oltvai et al., 1993; Yang et al., 1995) . BCL-XL prevents tBID from interacting with and activating BAX and BAK (Cheng et al., 2001 ). BCL-XL binds VDAC and affects its opening (Shimizu et al., 1999) . Moreover, BCL-XL sequesters p53 (Mihara et al., 2003) . These findings emphasize the importance of BCL-XL in the regulation of cell survival and death.
In this study, we have shown another mechanism underlying the antiapoptotic and prosurvival roles of BCL-XL. RASSF6 is a proapoptotic protein (Iwasa et al., 2015) .
Enforced expression of RASSF6 induces cell death (Allen et al., 2007; Ikeda et al., 2007 Ikeda et al., , 2009 Withanage et al., 2012) . RASSF6 depletion suppresses apoptosis caused by various stimuli such as tumor necrosis factor-α, superoxide, ultraviolet exposure and osmotic stress (Ikeda et al., 2009; Iwasa et al., 2013; Withanage et al., 2012) . We found that BCL-XL and RASSF6 interact with each other (Figure 1a,b) . The experiments using the deleted constructs of RASSF6 indicate that both the N-terminal and SARAH domains of RASSF6 bind BCL-XL (Figure 2b-d) . The binding of BCL-XL to the SARAH domain is weak, compared with the binding to the N-terminal region of RASSF6. Even so, as BCL-XL reduces the interaction between RASSF6 and MST kinases (Figure 3a) , which depends on the SARAH domains (Ikeda et al., 2009) , the binding to the SARAH domain is considered to be significant. BCL-XL may compete with MST kinases for the binding to the SARAH domain of RASSF6. MOAP1 binds to the N-terminal region of RASSF6 (Sarkar et al., 2017) . However, the interaction between MOAP1 and RASSF6 is not affected by BCL-XL (Figure 3b ). We speculate that MOAP1 and BCL-XL bind to the different sequences in the N-terminal region. The interaction between RASSF6 and MDM2 takes place at the multiple sites (Sarkar et al., 2017) . The N-terminal and RA domains of RASSF6 bind to the middle and C-terminal regions of MDM2, respectively. The SARAH domain binds to the border between the N-terminal and middle regions of MDM2. Therefore, BCL-XL is presumed to compete with MDM2 for the binding to the N-terminal and SARAH domains of RASSF6. Consistently, BCL-XL significantly reduces the interaction between RASSF6 and MDM2 (Figure 3c ). The RA domain of RASSF6 binds to the C-terminal RING-finger domain of MDM2 and is important to suppress MDM2-mediated p53 degradation (Sarkar et al., 2017) . As BCL-XL does not bind to the RA domain, we initially conjectured that RASSF6 may suppress MDM2-mediated p53 degradation even in the presence of BCL-XL. Contrary to our assumption, but consistent with the fact that BCL-XL weakens the interaction between RASSF6 and MDM2, BCL-XL blocks RASSF6-dependent enhancement of MDM2 ubiquitination and RASSF6-mediated stabilization of p53 ( Figure 5 ). We also tested the idea that RASSF6 suppresses the prosurvival role of BCL-XL to induce apoptosis. RASSF6 does not inhibit any interaction of BCL-XL with BAX, VDAC or p53 (Figure 4 ). BAX and VDAC bind to BH4 (Boise et al., 1993; Michels et al., 2013; Minn et al., 1999) . p53 is predicted to bind to BH4 and partial BH3 (Cheng et al., 2001 ). As BH4 is not implicated in the interaction with RASSF6, it is understandable that RASSF6 shows no effect on these interactions. tBID binds to BH3 of BCL-XL (Cheng et al., 1996) . We did not directly examine whether RASSF6 interacts with BH3, but we confirmed that RASSF6 interacts with the deletion construct of BCL-XL lacking BH4 and BH3 (BCL-XL-C; Figure 2e ). To more precisely characterize the interaction between RASSF6 and BCL-XL, it would be ideal to use BCL-XL mutants with point mutations instead of large deletions and avoid secondary effects. However, the current findings suggest that RASSF6 is likely to bind to BH1 and BH2, although the possibility that the transmembrane domain is required for the interaction is not excluded. Based on these findings, we speculate that RASSF6 does not interfere with the binding of tBID to BH3 and that RASSF6, unlike BH3-only sensitizers, does not liberate tBID from BCL-XL. All in all, we have not found the evidence that RASSF6 antagonizes the molecular interactions underlying the prosurvival roles of BCL-XL. To put our current findings together, we conclude that BCL-XL antagonizes RASSF6 and suppresses p53-mediated apoptosis and that RASSF6 does not promote apoptosis through inhibiting BCL-XL. BCL-XL promotes metastasis independently of its prosurvival role (Choi et al., 2016) . It is also intriguing to test whether RASSF6 suppresses the metastatic role of BCL-XL.
| EXPERIMENTAL PROCEDURES
4.1 | DNA constructions and virus production pCIneoFLAG-His6-FLAG (pCIneoFHF), pCIneoMyc, pCIneoGreen fluorescent protein (GFP), pCIneoEGFPC2, various pCIneoGFP-RASSF6 constructs (RASSF6, -N, -RA and -C), pCIneoMyc-RASSF6, pBudCGFP-RASSF6, pCIneoGFP-MST1, pCIneoGFP-MST2, pCGN-HA-UBC, pCIneoMycp53, pCIneoFHF-MDM2 and pCIneoGFP-MDM2 were described previously (Ikeda et al., 2007 (Ikeda et al., , 2009 Iwasa et al., 2013; Kudo et al., 2012; Sarkar et al., 2017) . pCIneoGFP encodes GFP protein followed by 30 amino acids including EFTRGTSRVDPGGRFPLVRVNASSRHDKIH (single letters represent amino acids), which are derived by the multiple cloning sites of pCIneo vector (Promega). Human BAX, BCL-XL and tBID were obtained by PCR on the mixture of human brain, lung and kidney libraries. The primers are as follows: H1812, 5′-gaattcatggacgggtccggggagca-3′ and H1813, 5′-gtcgactcagcccatcttcttccag-3′ for BAX; H3882, 5′-acgcgtatgtctcagagcaaccgggagctg-3′ and H3877, 5′-agtcg actcatttccgactgaagagtgagc-3′ for BCL-XL; and H3902, 5′-acgcgtgaattcaaccgcagcagccactcccgctt-3′ and H1715, 5′-ctc gaggtccatcccatttctggctaa-3′ for tBID. PCR products were ligated into pCIneoMyc, pCIneoFHF, pCIneomCherry, and pCIneoEGFP to generate pCIneoMyc-BCL-XL, pCIneoFHF-BCL-XL, pCIneomCherry-BCL-XL, pCIneoEGFP-BAX and pCIneoMyc-tBID. BCL-XL-N, BCL-XL-del N and BCL-XL-C contain 1-90, 83-233 and 124-233 amino acids of BCL-XL, respectively. NheI/NotI fragment from pCIneoMyc-BCL-XL was ligated into XbaI/NotI sites of pBudCGFP-RASSF6 to generate pBudcGFP-RASSF6-Myc-BCL-XL.
| Antibodies and reagents
The antibodies and the reagents were obtained from commercial sources: rabbit polyclonal anti-GFP (598) and rabbit polyclonal anti-α-tubulin (PM054; Medical and Biological Laboratories Co. Ltd., Nagoya, Japan); mouse monoclonal anti-GFP (B-2; SC-9996; Santa Cruz, Dallas, TX, USA); rabbit polyclonal anti-BCL-X (2762; Cell Signaling Technology, Danvers, MA, USA); mouse monoclonal anti-β-actin (A1978), mouse monoclonal anti-HA (12CA5), cycloheximide (C104450), pepstatin A (P5318) and Hoechst 33342 (Sigma-Aldrich, St. Louis, Dallas, TX, USA); Nethylmaleimide (15512-11) and MG-132 (09494-64; Nacalai Tesque, Tokyo, Japan); anti-DYKDDDDK-tag (014-22383), anti-DYKDDDDK-tag beads (016-22784) and leupeptin (334-40414; Wako Pure Chemical Industries, Osaka, Japan); protein G Sepharose 4 fast flow (GE Healthcare, Little Chalfont, UK); rabbit polyclonal anti-mCherry antibody (NBP2-25157; NOVUS Biologicals, Littleton, CO, USA); mouse monoclonal anticytochrome c (556432; BD 
| Immunoprecipitation experiments using exogenously expressed proteins
HEK293FT cells were plated at 1 × 10 6 cells/well in a 6-well plate. Twenty-four hours later, the indicated plasmids were transfected with PEI MAX. Twenty-four hours after transfection, the cells were treated with 10 μM MG-132 for 6 hr and then harvested and lysed in 500 μl lysis buffer A (25 mM TrisHCl pH 8.0, 100 mM NaCl, 7.5 mM MgCl 2 , 5 mM EDTA, 1% (v/v) Triton X-100, 50 μM p-(amidinophenyl) methanesulfonyl fluoride (APMSF), 3 mg/L pepstatin A, 10 mg/L leupeptin and 10 μM MG-132) and centrifuged at 20,000 g for 10 min at 4°C. The supernatant (the input) was incubated with 5 μl of anti-DYKDDDDK-tag beads or with anti-GFP antibody prefixed on 5 μl of protein G Sepharose 4 fast flow beads for 1 hr. The beads were washed three times with lysis buffer A or high salt lysis buffer (25 mM Tris-HCl pH 8.0, 500 mM NaCl, 7.5 mM MgCl 2 , 5 mM EDTA, 1% (v/v) Triton X-100, 50 μM APMSF, 3 mg/L pepstatin A, 10 mg/L leupeptin). The proteins of interest were detected in the inputs and the immunoprecipitates with the immunoblotting.
| Immunoprecipitation of endogenous proteins
SW480 cells from four 10-cm dishes (70%-80% confluency in each dish) were treated by 10 μM MG-132 for 6 hr, then harvested and lysed by 2 ml lysis buffer A for 10 min on ice. The mixtures were centrifuged at 20,000 g for 10 min at 4°C. The supernatant was incubated with 1 μg anti-RASSF6 antibody or control rabbit IgG for 2 hr at 4°C and was further incubated with 10 μl protein G Sepharose 4 fast flow beads (GE Healthcare) for 1 hr at 4°C. The beads were washed three times with the lysis buffer. The precipitates were analyzed by SDS-PAGE and immunoblotting.
| Apoptosis
HCT116 cells were plated at 1 × 10 5 cells/well in a 12-well plate. Twenty-four hours later, the cells were transfected with pCIneoGFP-RASSF6, pCIneoMyc-BCL-XL, pCIneoGFP-RASSF6/pCIneoMyc-BCL-XL or pBudCGFP-RASSF6-Myc-BCL-XL. Eighteen hours after transfection, the cells were fixed with 3.7% (w/v) formaldehyde for 5 min, neutralized by 50 mM glycine for 30 min at room temperature and permeabilized by PBS with 1% (w/v) BSA and 0.1% (v/v) Triton X-100 for 30 min. After that, the samples were incubated with anti-Myc or anti-cytochrome c antibody and with the appropriate secondary antibody. The nuclei were visualized with Hoechst 33342. Fifty GFP-or Myc-positive cells were observed for each set, and the ratio of the cells with condensed nuclei or cytochrome c release was calculated. The experiments were repeated three times.
| Statistical analysis
Statistical analyses were performed with Student's t test for comparison between two samples and analysis of variance with Bonferroni's post hoc test for multiple comparisons using Graphpad Prism software (Graphpad Software).
